Pipeline

At present our R&D portfolio includes nine first-in-class and BioBetters medicines based on three technological platforms – PolyXen, Histone and Gemacell.

Development of Innovative Technologies for the SynBio Project

Currently under Development

PolyXEN:

  • "Product A"- for treatment and/or prevention of anemia; contains a conjugate of EPO and polysialic acid as the active ingredient.
    Code:  SYN 20070131RU
  • "Product B" for treatment of febrile neutropenia; contains a conjugate of G-CSF and polysialic acid as the active ingredient.
    Code:  SYN 20111504RU
  • "Product C"  for treatment and/or prevention of diabetes mellitus and Alzheimer's disease; contains a conjugate of insulin and polysialic acid as the active ingredient.
    Code: SYN20090510RU
    Code: SYN20090110RU
  • "Product D"  for treatment of chronic hepatitis C; contains a conjugate of interferon alfa-2b and polysialic acid as the active ingredient.
    Code: SYN20110410RU
  • "Product E" – for treatment of growth hormone deficiency; contains a conjugate of human growth hormone and polysialic acid as the active ingredient.
    Code: SYN20100504RU

Histone

  • "Product F" – for treatment of hematological malignancies, Acute myeloid leukemia (AML) and non-Hodgkin lymphoma (NHL); contains histone H1.3 as the active ingredient.
    Code: SYN20051604RU
    Code: SYN20051504RU
  • "Product G" for treatment of peripheral vascular disease; contains histone H1.3 and kambiogenplasmid as the active ingredients.
    Code: SYN20112312RU
  • "Product H" for treatment of atherosclerosis; contains histone H1.3 and siRNA apoВ100 as the active ingredients.
    Code: SYN20110119RU

Gemacell

  • "Product I" for treatment of chronic diffuse liver disease; contains haematopoietic stem cells stem cells as its active ingredient.
    Code: SYN20092304RU